Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ganzaoning granule is an orally administered multi-herb traditional Chinese medicine formulation developed in China for fatty liver disease and related chronic liver conditions. It was derived from the earlier Ganfujian formula and has been evaluated clinically in a prospective randomized, double-blind, placebo-controlled 24-week study in people with chronic hepatitis B virus infection and non-alcoholic fatty liver disease. Its proposed biological effects on hepatic steatosis, inflammation, and fibrosis are based primarily on preclinical, phytochemical, and network-pharmacology evidence; a definitive clinically established molecular target has not been identified. ([chictr.org.cn](https://www.chictr.org.cn/showproj.html?proj=38802))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ganzaoning granule.